Horizon Pharma (HZNP) Tops Q4 EPS by 13c

Horizon Pharma (NASDAQ: HZNP) reported Q4 EPS of $0.64, $0.13 better than the analyst estimate of $0.51. Revenue for the quarter came in at $310.3 million versus the consensus estimate of $309.57 million.

GUIDANCE:

Horizon Pharma sees Q1 2017 revenue of $1.24-1.29 million, versus the consensus of $1.28 million.

• Full-year 2017 adjusted EBITDA guidance of $525 million to $575 million, representing year-over-year growth of 12 to 22 percent and approximately 43.5 percent of sales.

For earnings history and earnings-related data on Horizon Pharma (HZNP) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery